Skip to main content
BBIO logo

BBIO · BridgeBio Pharma, Inc. · Executive Compensation

Track BBIO — free
$76.03 -2.15 (-2.75%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$14.81B
Shares
194.80M
Volume · Nov 20 1.48M Avg daily vol (3M) 2.65M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Neil Kumar $14,944,585
Thomas Trimarchi $5,832,369
Brian Stephenson $684,661
Fiscal 2024
Executive Total
Neil Kumar $15,581,923
Thomas Trimarchi $6,502,058
Brian Stephenson $5,663,687
Fiscal 2023
Executive Total
Neil Kumar $12,158,626
Brian Stephenson $6,651,996
Fiscal 2022
Executive Total
Neil Kumar $6,674,437
Brian Stephenson $2,957,392
Fiscal 2021
Executive Total
Neil Kumar $25,626,959
Brian Stephenson $8,677,297
Fiscal 2020
Executive Total
Neil Kumar $10,054,909
Michael Henderson $7,991,241
Brian Stolz $5,240,851
Cameron Turtle $4,561,482
Brian Stephenson $4,163,933
Charles Homcy $1,855,805
Fiscal 2019
Executive Total
Neil Kumar $26,334,063
Brian Stolz $8,146,313
Charles Homcy $5,975,842
Brian Stephenson $4,198,967
Fiscal 2018
Executive Total
Brian Stephenson $2,347,115
Neil Kumar $450,000

Executive changes

Person Change Filed
Hannah A. Valantine, M.D. Appointed 2026-06-26
Frank P. McCormick, Ph.D. Appointed 2026-06-26
James C. Momtazee Appointed 2026-06-26
Randal W. Scott
“Dr. Scott’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2026-06-26
Thomas Trimarchi Appointed 2025-03-17
Brian C. Stephenson
“Dr. Stephenson's departure was not the result of a disagreement with the Company on any matters relating to the Company’s operations, policies or practices.”
Terminated 2025-03-17
Thomas Trimarchi Appointed 2024-07-23
Frank McCormick Appointed 2023-02-23
Brenton L. Saunders
“Dr. Scheller’s and Mr. Saunders’ resignations were not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2023-02-23
Richard H. Scheller
“Dr. Scheller’s and Mr. Saunders’ resignations were not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2023-02-23
Hannah A. Valantine Appointed 2021-10-26
Douglas Dachille Appointed 2021-08-23
Andrea Ellis Appointed 2021-08-23
Fred Hassan Appointed 2021-08-23

Leadership

Key facts CIK 1743881 CUSIP 10806X102 13F (30d) 465 filings 434 filers Visit website Investor relations